Shaw CA, August A, Bart S, Booth PJ, et al. A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults. Vaccine 2023 May 18:S0264-410X(23)00488-7. doi: 10.1016/j.vaccine.2023.
PMID: 37210308